DLA Piper represented Genomma Lab Internacional S.A.B. de C.V., a Mexican pharmaceutical and personal care company with an international presence, in its issuance of MX$1.25 billion in short-term debt securities in the form of Certificados Bursátiles.
The securities were placed in the course of 2020, through six issuances, and publicly offered in Mexican territory through the Mexican Stock Exchange (Bolsa Mexicana de Valores).
“We were pleased to bring our market-leading corporate and finance capabilities, as well as our experience advising companies on complex transactions in Mexico and throughout Latin America, to complete this debt securities issuance for Genomma Lab,” said DLA Piper partner Xavier Mangino, who led the firm’s deal team.
Along with Mangino, the DLA Piper team representing Genomma Lab included consultant Cristian Gastelum Rodriguez (both of Mexico City).
DLA Piper advises on all aspects of financing, across borders, sectors and financial products. The firm’s lawyers advise issuers, underwriters, selling shareholders, sponsors, arrangers, lead managers, originators, dealers, trustees and depositaries on a broad range of capital markets offerings, including equity, equity-linked and debt securities, structured and project financings and securitizations.
